Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
Lead SponsorGovernment of Hong Kong
The purpose of this study is to evaluate the efficacy, tolerability and safety of patients on long-acting Risperidone microshpheres injection. The major advantage of long-acting injection over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among schizophrenic and is a frequent cause of relapse.
Inclusion Criteria: Subjects with schizophrenia or another psychotic disorder according to DSM IV criteria who requires long term antipsychotic therapy Currently treated with either an atypical antipsychotic, other than risperidone, a conventional depot antipsychotic or oral conventional antipsychotic Subject has been symptomatically stable on a stable dose of an antipsychotic the last month Subject and/or patient's relative, guardian or legal representative has signed the informed consent form Exclusion Criteria: First antipsychotic treatment ever On clozapine during the last 3 month Serious unstable medical condition History or current symptoms of tardive dyskinesia History of neuroleptic malignant syndrome Pregnant or breast-feeding female Female patient of childbearing potential without adequate contraception. Participation in an investigational drug trial in the 30 days prior to selection Known intolerance/non-responder to risperidone